Challenges in the management of HIV infection: update on the role of probiotic supplementation as a possible complementary therapeutic strategy for cART treated people living with HIV/AIDS

References

• Poorolajal J, Hooshmand E, Mahjub H, et al. Survival rate of AIDS disease and mortality in HIV-infected patients: a meta-analysis. Public Health. 2016;139:3–12.
   PubMed Web of Science ®Google Scholar
• Pavlova-McCalla E, Trepka MJ, Ramirez G, et al. Socioeconomic status and survival of people with human immunodeficiency virus infection before and after the introduction of highly active antiretroviral therapy: a systematic literature review. J AIDS Clin Res. 2012;3.
   PubMedGoogle Scholar
• World Health Organization. HIV/AIDS. Geneva: WHO; [last accessed 2014 Nov 24] Available from: http://www.who.int/mediacentre/factsheets/fs360/en/; 2014
   Google Scholar
• World Health Organization. Number of deaths due to HIV/AIDS. Geneva: WHO. [last accessed 2014 Nov 24]. Available from: http://www.who.int/gho/hiv/epidemic_status/deaths_text/en/; 2014
   Google Scholar
• UNAIDS World AIDS Day Report 2015. Available from: http://www.unaids.org/en/resources/campaigns/WAD2015report.
   Google Scholar
• Knipe MD, Howle P. Fields virology. In: Chapter 50 HIV-1: pathogenesis, clinical manifestations, and treatment, sixth ed., Vol. 1, Lippincott Williams & Wilkins, a Wolters Kluwer, Philadelphia, PA, USA, 2013:1561–1583.
   Google Scholar
• Février M, Dorgham K, Rebollo A. CD4+ T cell depletion in Human Immunodeficiency Virus (HIV) infection: role of apoptosis. Viruses. 2011;3(5):586–612.
   PubMed Web of Science ®Google Scholar
• Dagenais-Lussier X, Mouna A, Routy JP, et al. Current topics in HIV-1 pathogenesis: the emergence of deregulated immuno-metabolism in HIV-infected subjects. Cytokine Growth Factor Rev. 2015;26:603–613.
   PubMed Web of Science ®Google Scholar
• Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet. 2006;368:489–504.
   PubMed Web of Science ®Google Scholar
• Salas JT, Chang TL. Microbiome in human immunodeficiency virus infection. Clin Lab Med. 2014;34:733–745.
   PubMed Web of Science ®Google Scholar
• Mahy M, Stover J, Stanecki K, et al. Estimating the impact of antiretroviral therapy: regional and global estimates of life-years gained among adults. J Sex Transm Dis. 2010;86:ii67–71.
   Google Scholar
• Ponte R, Mehraj V, Ghali P, et al. Reversing gut damage in HIV infection: using non-human primate models to instruct clinical research. EBioMedicine. 2016;4:40–49.
   PubMed Web of Science ®Google Scholar
• Probiotics in food: health and nutritional properties and guidelines for evaluation – FAO Food and Nutrition Paper 85. 2006. Available from: ftp://ftp.fao.org/docrep/fao/009/a0512e/a0512e00.pdf
   Google Scholar
• Gallo A, Passaro G, Gasbarrini A, et al. Modulation of microbiota as treatment for intestinal inflammatory disorders: an uptodate. World J Gastroenterol. 2016;22(32):7186–7202.
   PubMed Web of Science ®Google Scholar
• Mao N, Cubillos-Ruiz A, Cameron DE, et al. Probiotic strains detect and suppress cholera in mice. Sci Transl Med. 2018;10(445):pii: eaao2586.
   PubMed Web of Science ®Google Scholar
• Isabella VM, Ha BN, Castillo MJ, et al. Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat Biotechnol. 2018;36(9):857–864.
   PubMed Web of Science ®Google Scholar
• Alderton G Synthesizing a therapeutic probiotic. Science 07 SEP 2018:988.
   Google Scholar
• Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005;39(6):540–543.
   PubMed Web of Science ®Google Scholar
• Xia X, Chen J, Xia J, et al. Role of probiotics in the treatment of minimal hepatic encephalopathy in patients with HBV-induced liver cirrhosis. J Int Med Res. 2018;46(9):3596–3604.
   PubMed Web of Science ®Google Scholar
• Palma E, Recine N, Domenici L, et al. Long-term Lactobacillus rhamnosus BMX 54 application to restore a balanced vaginal ecosystem: a promising solution against HPV-infection. BMC Infect Dis. 2018;18(1):13.
   PubMed Web of Science ®Google Scholar
• Ceccarelli G, Cavallari EN, Savinelli S, et al. Clearance of human papillomavirus related anal condylomas after oral and endorectal multistrain probiotic supplementation in an HIV positive male: A case report. Medicine (Baltimore). 2018;97(16):e0329.
   PubMed Web of Science ®Google Scholar
• Tan H, Zhai Q, Chen W. Investigations of Bacteroides spp. towards next-generation probiotics. Food Res Int. 2019;116:637–644.
   PubMed Web of Science ®Google Scholar
• Maldonado Galdeano C, Cazorla SI, Lemme Dumit JM, et al. Beneficial effects of probiotic consumption on the immune system. Ann Nutr Metab. 2019;74(2):115–124.
   PubMed Web of Science ®Google Scholar
• Sarin SK, Pande A, Schnabl B. Microbiome as a therapeutic target in alcohol-related liver disease. J Hepatol. 2019;70(2):260–272.
   PubMed Web of Science ®Google Scholar
• Roy Sarkar S, Banerjee S. Gut microbiota in neurodegenerative disorders. J Neuroimmunol. 2019;15(328):98–104.
   Google Scholar
• Wei X, Jiang P, Liu J, et al. Association between probiotic supplementation and asthma incidence in infants: a meta-analysis of randomized controlled trials. J Asthma. 2019;18:1–12.
   Google Scholar
• Serrano-Villar S, Vásquez-Domínguez E, Pérez-Molina JA, et al. HIV, HPV, and microbiota: partners in crime? AIDS. 2017;31(4):591–594.
   PubMed Web of Science ®Google Scholar
• World gastroenterology organisation global guidelines. Probiotics and prebiotics. February 2017 [cited 2019 Jan 10]. Available from: http://www.worldgastroenterology.org/UserFiles/file/guidelines/Probiotics-and-prebiotics-English2017.pdf
   Google Scholar
• Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, et al. Mechanisms of action of probiotics. Adv Nutr. 2019;10(suppl_1):49–S66.
   PubMed Web of Science ®Google Scholar
• Patel R, DuPont HL. New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics. Clin Infect Dis. 2015;60(Suppl 2):S108–21.
   PubMed Web of Science ®Google Scholar
• Kotler DP, Gaetz HP, Lange M, et al. Enteropathy associated with the acquired immunodeficiency syndrome. Ann Int Med. 1984;101:421–428.
   PubMed Web of Science ®Google Scholar
• Pinacchio C, Corano Scheri G, Statzu M, et al. Type I/II interferon in HIV-1-infected patients: expression in gut mucosa and in peripheral blood mononuclear cells and its modification upon probiotic supplementation. J Immunol Res. 2018;2018:1738676.
   PubMedGoogle Scholar
• d’Ettorre G, Ceccarelli G, Andreotti M, et al. Analysis of Th17 and Tc17 Frequencies and antiviral defenses in gut-associated lymphoid tissue of chronic HIV-1 positive patients. Mediators Inflamm. 2015;2015:395484.
   PubMedGoogle Scholar
• Statzu M, Santinelli L, Viscido A, et al. Increased SAMHD1 transcript expression correlates with interferon-related genes in HIV-1-infected patients. Med Microbiol Immunol. 2018;18.
   Web of Science ®Google Scholar
• Sankaran S, George MD, Reay E, et al. Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration. J Virol. 2008;82:538–545.
   PubMed Web of Science ®Google Scholar
• Dillon SM, Lee EJ, Donovan AM, et al. Enhancement of HIV-1 infection and intestinal CD4+ T cell depletion ex vivo by gut microbes altered during chronic HIV-1 infection. Retrovirology. 2016;13:5.
   PubMed Web of Science ®Google Scholar
• Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200:749–759.
   PubMed Web of Science ®Google Scholar
• Guadalupe M, Reay E, Sankaran S, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol. 2003;77:11708–11717.
   PubMed Web of Science ®Google Scholar
• Mehandru S, Poles MA, Tenner-Racz K, et al. Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection. J Virol. 2007;81:599–612.
   PubMed Web of Science ®Google Scholar
• Chege D, Sheth PM, Kain T, et al. Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. AIDS. 2011;25:741–749.
   PubMed Web of Science ®Google Scholar
• Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol. 2007;19:281–286.
   PubMed Web of Science ®Google Scholar
• Kanwar B, Favre D, McCune JM. Th17 and regulatory T cells: implications for AIDS pathogenesis. Curr Opin HIV AIDS. 2010;5:151–157.
   PubMed Web of Science ®Google Scholar
• Liu JZ, Pezeshki M, Raffatellu M. Th17 cytokines and hostpathogen interactions at the mucosa: dichotomies of help and harm. Cytokine. 2009;48:156–160.
   PubMed Web of Science ®Google Scholar
• Kim CJ, Nazli A, Rojas OL, et al. A role for mucosal IL-22 production and Th22 cells in HIV-associated mucosal immunopathogenesis. Mucosal Immunol. 2012;5:670–680.
   PubMed Web of Science ®Google Scholar
• Brenchley JM, Douek DC. Microbial translocation across the GI tract. Annu Rev Immunol. 2012;30:149–173.
   PubMed Web of Science ®Google Scholar
• Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–1371.
   PubMed Web of Science ®Google Scholar
• Marchetti G, Cozzi-Lepri A, Merlini E, et al. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS. 2011;25:1385–1394.
   PubMed Web of Science ®Google Scholar
• Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev. 2013;26:2–18.
   PubMed Web of Science ®Google Scholar
• Zevin AS, McKinnon L, Burgener A, et al. Microbial translocation and microbiome dysbiosis in HIV-associated immune activation. Curr Opin HIV AIDS. 2016;11:182–190.
   PubMed Web of Science ®Google Scholar
• Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol. 2003;43:309–334.
   PubMed Web of Science ®Google Scholar
• Hubbard TD, Murray IA, Perdew GH. Indole and Tryptophan metabolism: endogenous and dietary routes to Ah receptor activation. Drug Metab Dispos. 2015;43(10):1522–1535.
   PubMed Web of Science ®Google Scholar
• Lamas B, Richard ML, Leducq V, et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med. 2016;22(6):598–605.
   PubMed Web of Science ®Google Scholar
• McMillan BJ, Bradfield CA. The aryl hydrocarbon receptor is activated by modified low-density lipoprotein. Proc Natl Acad Sci U S A. 2007;104(4):1412–1417.
   PubMed Web of Science ®Google Scholar
• Moura-Alves P, Faé K, Houthuys E, et al. AhR sensing of bacterial pigments regulates antibacterial defence. Nature. 2014;512(7515):387–392.
   PubMed Web of Science ®Google Scholar
• Zelante T, Iannitti RG, Cunha C, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity. 2013;39(2):372–385.
   PubMed Web of Science ®Google Scholar
• Nguyen NT, Nakahama T, Le DH, et al. Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research. Front Immunol. 2014;29(5):551.
   Google Scholar
• Zelante T, Iannitti RG, Fallarino F, et al. Tryptophan feeding of the IDO1-AhR axis in host-microbial symbiosis. Front Immunol. 2014;5:640.
   PubMed Web of Science ®Google Scholar
• Mehraj V, Routy JP. Tryptophan catabolism in chronic viral infections: handling uninvited guests. Int J Tryptophan Res. 2015;4(8):41–48.
   Google Scholar
• Monteleone I, Rizzo A, Sarra M, et al. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology. 2011;141(1):237–248. 248.e1.
   PubMed Web of Science ®Google Scholar
• Fernandes SM, Pires AR, Ferreira C, et al. Enteric mucosa integrity in the presence of a preserved innate interleukin 22 compartment in HIV type 1-treated individuals. J Infect Dis. 2014;210(4):630–640.
   PubMed Web of Science ®Google Scholar
• Qi Q, Hua S, Clish CB, et al. Plasma tryptophan-kynurenine metabolites are altered in Human Immunodeficiency Virus Infection and associated with progression of carotid artery atherosclerosis. Clin Infect Dis. 2018;67(2):235–242.
   PubMed Web of Science ®Google Scholar
• Byakwaga H, Boum Y 2nd, Huang Y, et al. The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy. J Infect Dis. 2014;210:383–391.
   PubMed Web of Science ®Google Scholar
• Hunt PW, Sinclair E, Rodriguez B, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014;210:1228–1238.
   PubMed Web of Science ®Google Scholar
• Chen J, Xun J, Yang J, et al. Plasma indoleamine 2,3-dioxygenase activity is associated with the size of HIV reservoir in patients receiving antiretroviral therapy. Clin Infect Dis. 2019;68(8):1274–1281.
   Web of Science ®Google Scholar
• Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature. 2007;449:804–810.
   PubMed Web of Science ®Google Scholar
• Peng L, He Z, Chen W, et al. Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res. 2007;2007(61):37–41.
   Google Scholar
• Hummelen R, Vos AP, Van’t Land B, et al. Altered host-microbe interaction in HIV: a target for intervention with pro- and pre-biotics. Int Rev Immunol. 2010;29:485–513.
   PubMed Web of Science ®Google Scholar
• Senghor B, Sokhna C, Ruimy R, et al. Gut microbiota diversity according to dietary habits and geographical provenance. Hum Microbiome J. 2018;7–8:1–9.
   Google Scholar
• Fuster D, Samet JH. Alcohol Use in Patients with Chronic Liver Disease. N Engl J Med. 2018;379(13):1251–1261.
   PubMed Web of Science ®Google Scholar
• Scagnolari C, Antonelli G. Type I interferon and HIV: subtle balance between antiviral activity, immunopathogenesis and the microbiome. Cytokine Growth Factor Rev. 2018;40:19–31.
   PubMed Web of Science ®Google Scholar
• Hansen MEB, Rubel MA, Bailey AG, et al. Population structure of human gut bacteria in a diverse cohort from rural Tanzania and Botswana. Genome Biol. 2019;20:16.
   PubMed Web of Science ®Google Scholar
• Fulcher JA, Hussain SK, Cook R, et al. Effects of substance use and sex practices on the intestinal microbiome during HIV-1 infection. J Infect Dis. 2018;218(10):1560–1570.
   PubMed Web of Science ®Google Scholar
• Noguera-Julian M, Rocafort M, Guillén Y, et al. Gut microbiota linked to sexual preference and HIV infection. EBioMedicine. 2016;5:135–146.
   PubMed Web of Science ®Google Scholar
• Armstrong AJS, Shaffer M, Nusbacher NM, et al. An exploration of Prevotella-rich microbiomes in HIV and men who have sex with men. Microbiome. 2018;6:198.
   PubMed Web of Science ®Google Scholar
• Lu W, Feng Y, Jing F, et al. Association between gut microbiota and CD4 recovery in HIV-1 infected patients. Front Microbiol. 2018;9:1451.
   PubMed Web of Science ®Google Scholar
• Fransen F, van Beek AA, Borghuis T, et al. The Impact of Gut Microbiota on Gender Specific Differences in Immunity. Front Immunol. 2017;8.
   Web of Science ®Google Scholar
• Mueller S, Saunier K, Hanisch C, et al. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. Appl Environ Microbiol. 2006;72(2):1027–1033.
   PubMed Web of Science ®Google Scholar
• d’Ettorre G, Borrazzo C, Pinacchio C, et al. Increased IL-17 and/or IFN-γ producing T cell subsets in gut mucosa of long-term treated HIV-1-infected women. AIDS. 2019;33(4):627–636.
   Web of Science ®Google Scholar
• Ji Y, Zhang F, Zhang R, et al. Changes in intestinal microbiota in HIV-1-infected subjects following cART initiation: influence of CD4+ T cell count. Emerg Microbes Infect. 2018;7(1):113.
   PubMedGoogle Scholar
• Nazli A, Chan O, Dobson-Belaire WN, et al. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog. 2010;6:e1000852.
   PubMed Web of Science ®Google Scholar
• Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV specific CD4+ T cells. Nature. 2002;417:95–98.
   PubMed Web of Science ®Google Scholar
• Tincati C, Douek DC, Marchetti G. Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection. AIDS Res Ther. 2016;11(13):19.
   Google Scholar
• Zilberman-Schapira G, Zmora N, Itav S, et al. The gut microbiome in human immunodeficiency virus infection. BMC Med. 2016;14(1):83.
   PubMedGoogle Scholar
• Dillon SM, Frank DN, Wilson CC. The gut microbiome and HIV-1 pathogenesis: a two-way street. AIDS. 2016;30(18):2737–2751.
   PubMed Web of Science ®Google Scholar
• Gootenberg DB, Paer JM, Luevano JM, et al. HIV-associated changes in the enteric microbial community: potential role in loss of homeostasis and development of systemic inflammation. Curr Opin Infect Dis. 2017;30(1):31–43.
   PubMed Web of Science ®Google Scholar
• Liu J, Williams B, Frank D, et al. The gut microbiome, and the mucosal immune system. J Immunol. 2017;198(2):605–614.
   PubMed Web of Science ®Google Scholar
• Ribeiro ABDTM, Heimesaat MM, Bereswill S. Changes of the intestinal microbiome-host homeostasis in HIV-infected individuals – a focus on the bacterial gut microbiome. Eur J Microbiol Immunol (Bp). 2017;7(3):158–167.
   PubMedGoogle Scholar
• Lilly DM, Stillwell RH. Probiotics: growth promoting factors produced by microorganisms. Science. 1965;147:747–748.
   PubMed Web of Science ®Google Scholar
• Vázquez-Castellanos JF, Serrano-Villar S, Jiménez-Hernández N, et al. Interplay between gut microbiota metabolism and inflammation in HIV infection. Isme J. 2018;12(8):1964–1976.
   PubMed Web of Science ®Google Scholar
• Manuzak JA, Hensley-McBain T, Zevin AS, et al. Enhancement of microbiota in healthy macaques results in beneficial modulation of mucosal and systemic immune function. Immunol. 2016;196:2401–2409.
   Web of Science ®Google Scholar
• Hensley-McBain T, Berard AR, Manuzak JA, et al. Intestinal damage precedes mucosal immune dysfunction in SIV infection. Mucosal Immunol. 2018;11:1429–1440.
   PubMed Web of Science ®Google Scholar
• Chahroudi A, Meeker T, Lawson B, et al. Mother-to-infant transmission of simian immunodeficiency virus is rare in sooty mangabeys and is associated with low viremia. J Virol. 2011;85:5757–5763.
   PubMed Web of Science ®Google Scholar
• Wood LF, Chahroudi A, Chen HL, et al. The oral mucosal immune environment and oral transmission of HIV/SIV. Immunol Rev. 2013;254:34–53.
   PubMed Web of Science ®Google Scholar
• Brenchley JM, Paiardini M, Knox KS, et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood. 2008;112:2826–2835.
   PubMed Web of Science ®Google Scholar
• Favre D, Lederer S, Kanwar B, et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog. 2009;5:e1000295.
   PubMed Web of Science ®Google Scholar
• Hartigan-O’Connor DJ, Hirao LA, McCune JM, et al. Th17 cells and regulatory T cells in elite control over HIV and SIV. Curr Opin HIV AIDS. 2011;6:221–227.
   PubMed Web of Science ®Google Scholar
• Brenchley JM. Mucosal immunity in human and simian immunodeficiency lentivirus infections. Mucosal Immunol. 2013;6:657–665.
   PubMed Web of Science ®Google Scholar
• Cecchinato V, Trindade C, Laurence A, et al. Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficienty virus-infected macaques. Mucosal Immunol. 2008;1:279–288.
   PubMed Web of Science ®Google Scholar
• Williams B, Landay A, Presti RM. Microbiome alterations in HIV infection a review. Cell Microbiol. 2016;18:645–651.
   PubMed Web of Science ®Google Scholar
• Glavan TW, Gaulke CA, Hirao LA, et al. SIV-infection-driven changes of pattern recognition receptor expression in mesenteric lymph nodes and gut microbiota dysbiosis. J Med Primatol. 2015;44:241–252.
   PubMed Web of Science ®Google Scholar
• Moeller AH, Shilts M, Li Y, et al. SIV-induced instability of the chimpanzee gut microbiome. Cell Host Microbe. 2013;14:340–345.
   PubMed Web of Science ®Google Scholar
• Vujkovic-Cvijin I, Swainson LA, Chu SN, et al. Gut-Resident lactobacillus abundance associates with IDO1 inhibition and Th17 dynamics in SIV-infected macaques. Cell Rep. 2015;13:1589–1597.
   PubMed Web of Science ®Google Scholar
• Sui Y, Dzutsev A, Venzon D, et al. Influence of gut microbiome on mucosal immune activation and SHIV viral transmission in naive macaques. Mucosal Immunol. 2018;11(4):1219–1229.
   PubMed Web of Science ®Google Scholar
• Mudd JC, Brenchley JM. Gut mucosal barrier dysfunction, microbial dysbiosis, and their role in HIV-1 disease progression. J Infect Dis. 2016;214(Suppl 2):S58–66.
   PubMedGoogle Scholar
• Klatt NR. Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J Clin Invest. 2013;123:903–907.
   PubMed Web of Science ®Google Scholar
• Ortiz AM, Klase ZA, DiNapoli SR, et al. IL-21 and probiotic therapy improve Th17 frequencies, microbial translocation, and microbiome in ARV-treated, SIV-infected macaques. Mucosal Immunol. 2016;9:458–467.
   PubMed Web of Science ®Google Scholar
• Hirao LA, Grishina I, Bourry O, et al. Early mucosal sensing of SIV infection by paneth cells induces IL-1β production and initiates gut epithelial disruption. PLoS Pathog. 2014;10(8):e1004311.
   PubMed Web of Science ®Google Scholar
• Desselberger U. The mammalian intestinal microbiome: composition, interaction with the immune system, significance for vaccine efficacy, and potential for disease therapy. Pathogens. 2018;7(3):pii: E57.
   PubMed Web of Science ®Google Scholar
• Dubourg G, Surenaud M, Lévy Y, et al. Microbiome of HIV-infected people. Microb Pathog. 2017;106:85–93.
   PubMed Web of Science ®Google Scholar
• Wilson NL, Moneyham LD, Alexandrov AW. A systematic review of probiotics as a potential intervention to restore gut health in HIV infection. J Assoc Nurses AIDS Care. 2013;24:98–111.
   PubMed Web of Science ®Google Scholar
• Vanderpool C, Yan F, Polk DB. Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis. 2008;14:1585–1596.
   PubMed Web of Science ®Google Scholar
• Wildt S, Munck LK, Vinter-Jensen L, et al. Probiotic treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial with Lactobacillus acidophilus and Bifidobacterium animalis subsp. Lactis Inflammation Bowel Dis. 2006;12:395–401.
   PubMed Web of Science ®Google Scholar
• Estes JD, Harris LD, Klatt NR, et al. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog. 2010;6:e1001052.
   PubMed Web of Science ®Google Scholar
• Mavigner M, Cazabat M, Dubois M, et al. Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J Clin Invest. 2012;122:62–69.
   PubMed Web of Science ®Google Scholar
• d’Ettorre G, Paiardini M, Zaffiri L, et al. HIV persistence in the gut mucosa of HIV-infected subjects undergoing antiretroviral therapy correlates with immune activation and increased levels of LPS. Curr HIV Res. 2011;9:148–153.
   PubMed Web of Science ®Google Scholar
• d’Ettorre G, Paiardini M, Ceccarelli G, et al. HIV-associated immune activation: from bench to bedside. AIDS Res Hum Retroviruses. 2011;27:355–364.
   PubMed Web of Science ®Google Scholar
• Irvine SL, Hummelen R, Hekmat S. Probiotic yogurt consumption may improve gastrointestinal symptoms, productivity, and nutritional intake of people living with human immunodeficiency virus in Mwanza, Tanzania. Nutr Res. 2011;31:875–881.
   PubMed Web of Science ®Google Scholar
• Saint-Marc T, Rossello-Prats L, Touraine JL. Efficacy of Saccharomyces boulardii in the treatment of diarrhea in AIDS. Ann Med Internet (Paris). 1991;142:64–65.
   PubMedGoogle Scholar
• Saint-Marc T, Blehaut H, Musial C, et al. Diarrhees en relation avec le sida: essai en double aveugle de Saccharomyces Boulardii. Semaine Des Hopitaux. 1995;71:735–741.
   Google Scholar
• Salminen MK, Tynkkynen S, Rautelin H, et al. The efficacy and safety of probiotic Lactobacillus rhamnosus GG on prolonged, noninfectious diarrhea in HIV patients on antiretroviral therapy: a randomized, placebo-controlled, crossover study. HIV Clin Trials. 2004;5:183–191.
   PubMed Web of Science ®Google Scholar
• Trois L, Cardoso EM, Miura E. Use of probiotics in HIV-infected children: a randomized double-blind controlled study. J Trop Pediatr. 2008;54:19–24.
   PubMed Web of Science ®Google Scholar
• Hemsworth JC, Hekmat S, Reid G. Micronutrient supplemented probiotic yogurt for HIV-infected adults taking HAART in London, Canada. Gut Microbes. 2012;3:414–419.
   PubMed Web of Science ®Google Scholar
• Falasca K, Vecchiet J, Ucciferri C, et al. Effect of probiotic supplement on cytokine levels in HIV-infected individuals: a preliminary study. Nutrients. 2015;7:8335–8347.
   PubMed Web of Science ®Google Scholar
• Hummelen R, Changalucha J, Butamanya NL, et al. Effect of 25 weeks probiotic supplementation on immune function of HIV patients. Gut Microbes. 2011;2(2):80–85.
   PubMed Web of Science ®Google Scholar
• Anukam KC, Osazuwa EO, Osadolor HB, et al. Yogurt containing probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 helps resolve moderate diarrhea and increases CD4 count in HIV/AIDS patients. J Clin Gastroenterol. 2008;42(3):239–243.
   PubMed Web of Science ®Google Scholar
• d’Ettorre G, Ceccarelli G, Giustini N, et al. Probiotics reduce inflammation in antiretroviral treated, HIV-infected individuals: results of the “Probio-HIV” clinical trial. PLoS One. 2015;10:e0137200.
   PubMed Web of Science ®Google Scholar
• González-Hernández LA, Jave-Suarez LF, Fafutis-Morris M, et al. Synbiotic therapy decreases microbial translocation and inflammation and improves immunological status in HIV-infected patients: a double-blind randomized controlled pilot trial. Nutr J. 2012;11:90.
   PubMed Web of Science ®Google Scholar
• Villar-García J, Hernández JJ, Güerri-Fernández R, et al. Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trial. J Acquir Immune Defic Syndr. 2015;68:256–263.
   PubMed Web of Science ®Google Scholar
• d’Ettorre G, Rossi G, Scagnolari C, et al. Probiotic supplementation promotes a reduction in T-cell activation, an increase in Th17 frequencies, and a recovery of intestinal epithelium integrity and mitochondrial morphology in ART-treated HIV-1-positive patients. Immun Inflamm Dis. 2017;5:244–260.
   PubMed Web of Science ®Google Scholar
• Arnbjerg CJ, Vestad B, Hov JR, et al. Effect of Lactobacillus rhamnosus GG supplementation on intestinal inflammation assessed by PET/MRI scans and gut microbiota composition in HIV-infected individuals. J Acquir Immune Defic Syndr. 2018 ;78(4):450–457.
   PubMed Web of Science ®Google Scholar
• Kim CJ, Walmsley SL, Raboud JM, et al. Can probiotics reduce inflammation and enhance gut immune health in people living with HIV: study designs for the probiotic visbiome for inflammation and translocation (PROOV IT) pilot trials. HIV Clin Trials. 2016;17:147–157.
   PubMed Web of Science ®Google Scholar
• Presti R, Kitch DW, Andrade A, et al. Effects of probiotic Visbiome ES on colonic mucosal CD4 cells: results from A5352S. Abstract Number 274. Conference on Retrovirus and Opportunistic Infections (CROI), Boston, Massachusetts, March 4–7, 2018. (http://www.croiconference.org/sessions/effects-probiotic-visbiome-es-colonic-mucosal-cd4-cells-results-a5352s).
   Google Scholar
• Carter GM, Esmaeili A, Shah H, et al. Probiotics in human immunodeficiency virus infection: a systematic review and evidence synthesis of benefits and risks. Open Forum Infect Dis. 2016;3. ofw164.
   Web of Science ®Google Scholar
• Sessa L, Reddel S, Manno E. Distinct gut microbiota profile in ART-treated perinatally HIV-infected patients associated with cardiac and inflammatory biomarkers. AIDS. 2019 ;33:1001–1011.
   PubMed Web of Science ®Google Scholar
• Naito Y, Uchiyama K, Takagi T. A next-generation beneficial microbe: akkermansia muciniphila. J Clin Biochem Nutr. 2018;63(1):33–35.
   PubMed Web of Science ®Google Scholar
• O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7(7):688–693.
   PubMed Web of Science ®Google Scholar
• Ceccarelli G, Fratino M, Selvaggi C, et al. A pilot study on the effects of probiotic supplementation on neuropsychological performance and microRNA-29a-c levels in antiretroviral-treated HIV-1-infected patients. Brain Behav. 2017;7(8):e00756.
   PubMed Web of Science ®Google Scholar
• Ceccarelli G, Brenchley JM, Cavallari EN, et al. Impact of high-dose multi-strain probiotic supplementation on neurocognitive performance and central nervous system immune activation of HIV-1 infected individuals. Nutrients. 2017;9(11):pii: E1269.
   PubMed Web of Science ®Google Scholar
• Scagnolari C, Corano Scheri G, Selvaggi C, et al. Probiotics differently affect gut-associated lymphoid tissue indolamine-2,3-dioxygenase mRNA and cerebrospinal fluid neopterin levels in antiretroviral-treated HIV-1 infected patients: a pilot study. Int J Mol Sci. 2016;17:1639.
   Web of Science ®Google Scholar
• Scheri GC, Fard SN, Schietroma I, et al. Modulation of tryptophan/serotonin pathway by probiotic supplementation in Human Immunodeficiency Virus-positive patients: preliminary results of a new study approach. Int J Tryptophan Res. 2017;10:1178646917710668.
   Web of Science ®Google Scholar
• Stiksrud B, Nowak P, Nwosu FC, et al. Reduced levels of D-dimer and changes in gut microbiota composition after probiotic intervention in HIV infected individuals on stable ART. J Acquir Immune Defic Syndr. 2015;70:329–337.
   PubMed Web of Science ®Google Scholar
• El-Far M, Tremblay CL. Gut microbial diversity in HIV infection post combined antiretroviral therapy: a key target for prevention of cardiovascular disease. Curr Opin HIV AIDS. 2018;13(1):38–44.
   PubMed Web of Science ®Google Scholar
• Hempel S, Newberry S, Ruelaz A, et al. Safety of probiotics used to reduce risk and prevent or treat disease. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
   Google Scholar
• Wallace TC, MacKay D. The safety of probiotics: considerations following the 2011U.S. Agency for health research and quality report. J Nutr. 2011;141:1923–1924.
   PubMed Web of Science ®Google Scholar
• Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med. 1998;105:71–72.
   PubMed Web of Science ®Google Scholar
• Barton LL, Rider ED, Coen RW. Bacteremic infection with Pediococcus: vancomycin resistant opportunist. Pediatrics. 2001;107:775–776.
   PubMed Web of Science ®Google Scholar
• De Groote MA, Frank DN, Dowell E, et al. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J. 2005;24:278–280.
   PubMed Web of Science ®Google Scholar
• Richard V, Van der Auwera P, Snoeck R, et al. Nosocomial bacteremia caused by Bacillus species. Eur J Clin Microbiol Infect Dis. 1988;7:783–785.
   PubMed Web of Science ®Google Scholar
• Tommasi C, Equitani F, Masala M, et al. Diagnostic difficulties of Lactobacillus casei bacteraemia in immunocompetent patients: a case report. J Med Case Rep. 2008;2:315.
   PubMedGoogle Scholar
• Vahabnezhad E, Mochon AB, Wozniak LJ, et al. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol. 2013;47:437–439.
   PubMed Web of Science ®Google Scholar
• Presterl E, Kneifel W, Mayer HK, et al. Endocarditis by Lactobacillus rhamnosus due to yogurt ingestion? Scand J Infect Dis. 2001;33:710–714.
   PubMedGoogle Scholar
• Santino I, Alari A, Bono S, et al. Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum. Int J Immunopathol Pharmacol. 2014;27:143–146.
   PubMed Web of Science ®Google Scholar
• Ledoux D, Labombardi VJ, Karter D. Lactobacillus acidophilus bacteraemia after use of a probiotic in a patient with AIDS and Hodgkin’s disease. Int J STD AIDS. 2006;17:280–282.
   PubMed Web of Science ®Google Scholar
• Haghighat L, Crum-Cianflone NF. The potential risks of probiotics among HIV-infected persons: bacteraemia due to Lactobacillus acidophilus and review of the literature. Int J STD AIDS. 2016;27(13):1223–1230.
   PubMed Web of Science ®Google Scholar
• Grześkowiak Ł, Isolauri E, Salminen S, et al. Manufacturing process influences properties of probiotic bacteria. Br J Nutr. 2011;105:887–894.
   PubMed Web of Science ®Google Scholar
• Adawi D, Ahrné S, Molin G. Effects of different probiotic strains of Lactobacillus and Bifidobacterium on bacterial translocation and liver injury in an acute liver injury model. Int J Food Microbiol. 2001;70:213–220.
   PubMed Web of Science ®Google Scholar
• Özdemir Ö. Various effects of different probiotic strains in allergic disorders: an update from laboratory and clinical data. Clin Exp Immunol. 2010;160:295–304.
   PubMed Web of Science ®Google Scholar
• Cinque B, La Torre C, Lombardi F, et al. Production conditions affect the in vitro anti-tumoral effects of a high concentration multi-strain probiotic preparation. PLoS One. 2016;11:e0163216.
   PubMed Web of Science ®Google Scholar
• Trinchieri V, Laghi L, Vitali B, et al. Efficacy and safety of a multistrain probiotic formulation depends from manufacturing. Front Immunol. 2017;6(8):1474.
   Google Scholar
• Ceccarelli G, Vullo V, d’Ettorre G. Single-strain vs multi-strain probiotic supplementation strategy against rheumatoid arthritis. Arthritis Rheumatol. 2018;70(2):320–321
   PubMedGoogle Scholar
• McFarland LV, Evans CT, Goldstein EJC. Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. Front Med (Lausanne). 2018;7(5):124.
   Google Scholar